+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Brain Tumor Drugs Global Market Report 2020

  • ID: 4871545
  • Report
  • December 2019
  • Region: Global
  • 200 pages
  • The Business Research Company
1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AbbVie
  • AstraZeneca
  • Celgene
  • Hoffmann- La Roche
  • Merck & Co. Inc.
  • Philips Healthcare
  • MORE
Brain Tumour Drugs Market Global Report 2020 from the author provides strategists, marketers and senior management with the critical information they need to assess the global brain tumour drugs market.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.
Description:
Where is the largest and fastest growing market for the brain tumour drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Brain Tumour Drugs Market Global Report from the author answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market:
  • The Market Characteristics section of the report defines and explains the market.
  • The Market Size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
  • Market Segmentations break down market into sub markets.
  • The Regional and Country section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
  • Competitive Landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The Trends and Strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.
Scope
  • Markets Covered: 1) By Drugs: Temozolomide, Carmustine, Cisplatin, Bevacizumab, Geftinib, Erlotinib 2) By End User: Hospital Pharmacies, Clinics, Others
  • Companies Mentioned: Pfizer Inc., Shimadzu Corporation, Toshiba Medical Systems, Merck & Co. Inc., AstraZeneca
  • Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA
  • Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
  • Time Series: Five years historic and forecast.
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie
  • AstraZeneca
  • Celgene
  • Hoffmann- La Roche
  • Merck & Co. Inc.
  • Philips Healthcare
  • MORE
1. Executive Summary

2. Brain Tumor Drugs Market Characteristics

3. Brain Tumor Drugs Market Size And Growth
3.1. Global Brain Tumor Drugs Historic Market, 2015 - 2019, $ Billion
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Global Brain Tumor Drugs Forecast Market, 2019 - 2022F, 2025F, 2030F, $ Billion
3.2.1. Drivers Of The Market
3.2.2. Restraints On the Market

4. Brain Tumor Drugs Market Segmentation
4.1. Global Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
  • Temozolomide
  • Carmustine
  • Cisplatin
  • Bevacizumab
  • Geftinib
  • Erlotinib
4.2. Global Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
  • Hospital Pharmacies
  • Clinics
  • Others
5. Brain Tumor Drugs Market Regional And Country Analysis
5.1. Global Brain Tumor Drugs Market, Split By Region, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
5.2. Global Brain Tumor Drugs Market, Split By Country, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

6. Asia-Pacific Brain Tumor Drugs Market
6.1. Asia-Pacific Brain Tumor Drugs Market Overview
6.2. Asia-Pacific Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
6.3. Asia-Pacific Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

7. China Brain Tumor Drugs Market
7.1. China Brain Tumor Drugs Market Overview
7.2. China Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F,$ Billion
7.3. China Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F,$ Billion

8. India Brain Tumor Drugs Market
8.1. India Brain Tumor Drugs Market Overview
8.2. India Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
8.3. India Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

9. Japan Brain Tumor Drugs Market
9.1. Japan Brain Tumor Drugs Market Overview
9.2. Japan Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
9.3. Japan Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

10. Australia Brain Tumor Drugs Market
10.1. Australia Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
10.2. Australia Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

11. Indonesia Brain Tumor Drugs Market
11.1. Indonesia Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
11.2. Indonesia Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

12. South Korea Brain Tumor Drugs Market
12.1. South Korea Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
12.2. South Korea Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

13. Western Europe Brain Tumor Drugs Market
13.1. Western Europe Brain Tumor Drugs Market Overview
13.2. Western Europe Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
13.3. Western Europe Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

14. UK Brain Tumor Drugs Market
14.1. UK Brain Tumor Drugs Market Overview
14.2. UK Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
14.3. UK Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

15. Germany Brain Tumor Drugs Market
15.1. Germany Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
15.2. Germany Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

16. France Brain Tumor Drugs Market
16.4. France Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
16.5. France Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

17. Eastern Europe Brain Tumor Drugs Market
17.1. Eastern Europe Brain Tumor Drugs Market Overview
17.2. Eastern Europe Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
17.3. Eastern Europe Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

18. Russia Brain Tumor Drugs Market
18.1. Russia Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
18.2. Russia Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

19. North America Brain Tumor Drugs Market
19.1. North America Brain Tumor Drugs Market Overview
19.2. North America Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
19.3. North America Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

20. USA Brain Tumor Drugs Market
20.1. USA Brain Tumor Drugs Market Overview
20.2. USA Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
20.3. USA Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

21. South America Brain Tumor Drugs Market
21.1. South America Brain Tumor Drugs Market Overview
21.2. South America Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
21.3. South America Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

22. Brazil Brain Tumor Drugs Market
22.1. Brazil Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
22.2. Brazil Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

23. Middle East Brain Tumor Drugs Market
23.1. Middle East Brain Tumor Drugs Market Overview
23.2. Middle East Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
23.3. Middle East Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

24. Africa Brain Tumor Drugs Market
24.1. Africa Brain Tumor Drugs Market Overview
24.2. Africa Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
24.3. Africa Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

25. Brain Tumor Drugs Market Competitive Landscape And Company Profiles
25.1. Brain Tumor Drugs Market Competitive Landscape
25.2. Brain Tumor Drugs Market Company Profiles
25.2.1. Pfizer Inc.
25.2.1.1. Overview
25.2.1.2. Products and Services
25.2.1.3. Strategy
25.2.1.4. Financial Performance
25.2.2. Shimadzu Corporation
25.2.2.1. Overview
25.2.2.2. Products and Services
25.2.2.3. Strategy
25.2.2.4. Financial Performance
25.2.3. Toshiba Medical Systems
25.2.3.1. Overview
25.2.3.2. Products and Services
25.2.3.3. Strategy
25.2.3.4. Financial Performance
25.2.4. Merck & Co. Inc.
25.2.4.1. Overview
25.2.4.2. Products and Services
25.2.4.3. Strategy
25.2.4.4. Financial Performance
25.2.5. AstraZeneca
25.2.5.1. Overview
25.2.5.2. Products and Services
25.2.5.3. Strategy
25.2.5.4. Financial Performance

26. Key Mergers And Acquisitions In The Brain Tumor Drugs Market

27. Brain Tumor Drugs Market Trends And Strategies

28. Product Pipeline Analysis

29. Brain Tumor Drugs Market Future Outlook and Potential Analysis

30. Appendix
Note: Product cover images may vary from those shown
3 of 5

FEATURED COMPANIES

  • AbbVie
  • AstraZeneca
  • Celgene
  • Hoffmann- La Roche
  • Merck & Co. Inc.
  • Philips Healthcare
  • MORE
The brain tumor drugs market consist of sales of drugs which are used to cure a mass growth of abnormal cells in the human brain. These drugs are either used alone or in combinations, depending on the type, size and locations of the tumor. For example, Afinitor (Everolimus), BiCNU (Carmustine), Everolimus, Carmustine, Temozolomide and Avastin (Bevacizumab) are some of the drugs included in this market.

The global brain tumor drugs market was valued at about $2.4 billion in 2018 and is expected to grow to $3.41 billion at a CAGR of 9.2% through 2022.

North America was the largest region in the brain tumor drugs market in 2018. This region is expected to remain the largest during the next five years. The brain tumor drugs market in Asia Pacific is forecasted to register the highest CAGR during 2018-2023.

The major driving factor responsible for the growth of Brain Tumor market is the increasing prevalence of Neurological Disorders, worldwide. Neurological Disorders are identified as one of the most prevalent disorders, due to longer life expectancy, increasing exposure to infections and sedentary lifestyle. In 2015, these disorders were ranked as the leading cause group of Disability Adjusted Life Years (DALYs), , which is the number of years lost due to ill-health, disability or early death. For example, as per the North American Brain Tumor Society, around 700,000 people in the region were suffering from Brain Tumors in 2015, which increased by around 78,000 people in 2016. . The increasing number of patients with neurological disorders including brain tumor, is leading to a rise in the demand for the drugs used in their treatment.

Increasing use of targeted therapies is acting as a restraint on the Brain Tumor drugs market. Targeted cancer therapies are drugs or substances which block the growth of cancer by interfering with molecules that are more specifically involved in cancer cell progression than in normal cell activity. The goal of targeted cancer therapies is to eliminate cancerous cells in the body while leaving normal cells unharmed. By focusing on changes in the cell that are specific to cancer, this therapy may prove to be more effective than traditional chemotherapy and radiotherapy. For example, Everolimus is a targeted therapy that specially blocks the cancer cells from growing and spreading. Similarly, Bevacizumab prevents regeneration of cancer cells unlike chemical drugs which cannot prevent regeneration. This rising popularity of targeted therapies is expected to affect the sales of conventional chemical Brain Tumor drugs, thus restraining the growth of the market during the forecast period.

Companies in the brain tumor market are focusing on the use of nanotechnology for treatment. The nanoparticles are being used to carry drugs in combination, directly to the cancer cells or into the tumor. This technology has also led to a reduction in dosage of the drugs, improved shelf life and reduce toxicity. A few nanodrugs are proving to be useful in overcoming the blood-brain barrier, which was a significant challenge in the treatment of Brain tumors. For instance, Liposomes nanoparticles facilitate easy delivery of drugs to the core cancer cells, these particles if coated with transferrin can even pass through the blood-brain barrier. Companies like GE Healthcare, Sigma-Tau Pharmaceuticals Inc., Johnson & Johnson, Merck & Company Inc., Pfizer, Inc., Celgene Corporation are adopting this technology to improve the available techniques of medication and treatment.

The Brain Tumor market is governed by regulatory authorities such as the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). The regulatory body requires the companies in the industry to adhere to same rules for conducting clinical trials, consistently throughout the region. These rules are relating to transparency of information and maintaining safety standards while conducting clinical trials of newly discovered drugs and therapies throughout the EU. The regulation also encourages cross-border cooperation for making the scope of these clinical tests wider.

In 2019, Bristol-Myers Squibb acquired Celgene Corporation for an equity value of approximately $74 billion. Celgene Corporation is a biotechnology company that focuses on discovering and commercializing medicines for Cancer and inflammatory disorders. Celgene was founded in 1986 and is headquartered in New Jersey, United States. The acquisition is expected to help Bristol-Myers Squibb in expediting the development of drugs for oncology, inflammatory, cardiovascular and immunologic diseases. The acquisition also enhanced reach and scalability of the existing firms.

Major players in the market are Pfizer Inc., Shimadzu Corporation, Toshiba Medical Systems, Merck & Co. Inc., AstraZeneca
Note: Product cover images may vary from those shown
4 of 5
  • Pfizer Inc.
  • Shimadzu Corporation
  • Toshiba Medical Systems
  • Merck & Co. Inc.
  • AstraZeneca
  • Carestream Health
  • Philips Healthcare
  • Siemens Healthineers
  • Hitachi Medical Corporation
  • GE Healthcare
  • Novartis AG
  • Bristol-Myers Squibb
  • AbbVie
  • Astellas Pharma
  • Roche
  • Celgene
  • Johnson & Johnson
  • Genetech U.S.A
  • Hoffmann- La Roche
  • Antisense Pharma
  • Macleods Pharmaceutical Limited
  • Mankind Pharma
  • Dr. Reddys Laboratories Ltd
Note: Product cover images may vary from those shown
5 of 5

Loading
LOADING...

Adroll
adroll